CompletedNot Applicable

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy

Algeria, Egypt, Indonesia1,987 participantsStarted 2014-06-27

Plain-language summary

Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute venous thoromboembolism (VTE). The main goal is to analyze long-term safety in the use of rivaroxaban in the treatment of acute VTE in routine clinical practice.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female or male patients, who are at \>=18 years * Diagnosis of acute DVT and/or PE, objectively confirmed * Indication for anticoagulation therapy for at least 12 weeks * Willing to participate in this study and available for follow-up Exclusion Criteria: * Exclusion criteria must be read in conjunction with the local product information.

What they're measuring

Number of major bleedings defined as overt bleeding

Timeframe: Up to 2 years

Number of patients with symptomatic recurrent venous thromboembolic events

Timeframe: Up to 2 years

All cause mortality

Timeframe: Up to 2 years

Trial details

NCT IDNCT02210819

SponsorBayer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2016-11-03

View on ClinicalTrials.gov More Deep Vein Thrombosis (DVT) trials